Skip to main content

CORRECTION article

Front. Endocrinol., 14 March 2022
Sec. Bone Research
Volume 13 - 2022 | https://doi.org/10.3389/fendo.2022.877512

Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

This article is a correction to:

  1. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

    1. Read original article
Kaleen N. HayesKaleen N. Hayes1Ulrike Baschant*Ulrike Baschant2*Barbara Hauser,Barbara Hauser3,4Andrea M. BurdenAndrea M. Burden5Elizabeth M. WinterElizabeth M. Winter6
  • 1Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States
  • 2Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
  • 3Rheumatic Disease Unit, Western General Hospital, National Health Service (NHS) Lothian, Edinburgh, United Kingdom
  • 4Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
  • 5Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology [Eidgenössische Technische Hochschule (ETH)] Zurich, Zurich, Switzerland
  • 6Center for Bone Quality, Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands

A Corrigendum on
When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

by Hayes KN, Baschant U, Hauser B, Burden AM and Winter EM (2021). Front. Endocrinol. 12:782118. doi: 10.3389/fendo.2021.782118

In the article as published originally, Elizabeth M. Winter was erroneously presented as the corresponding author instead of Ulrike Baschant.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: glucocorticoid-induced osteoporosis, glucocorticoids, bone fractures, bone density, anti-resorptive treatment, bone density conservation agents, bisphosphonates, teriparatide

Citation: Hayes KN, Baschant U, Hauser B, Burden AM and Winter EM (2022) Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis. Front. Endocrinol. 13:877512. doi: 10.3389/fendo.2022.877512

Received: 16 February 2022; Accepted: 23 February 2022;
Published: 14 March 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Hayes, Baschant, Hauser, Burden and Winter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ulrike Baschant, VWxyaWtlLkJhc2NoYW50QHVuaWtsaW5pa3VtLWRyZXNkZW4uZGU=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.